Auditor flags up delays in roll out of electronic patient record in Wales

Auditor flags up delays in roll out of electronic patient record in Wales

January 17 2018 Delays and issues with functionality in the electronic patient record are causing...

RPS launches consultation on a proposed statement on the role of the pharmacist

RPS launches consultation on a proposed statement on the role of the pharmacist

January 8 2018 The Royal Pharmaceutical Society is asking for views on a statement it has drawn...

CQC will get powers to extend coverage to include online medical services

CQC will get powers to extend coverage to include online medical services

January 4 2018 The Care Quality Commission will be required to inspect healthcare services, such...

Second consultation on restricting OTC medicines on NHS prescription runs to March 14

Second consultation on restricting OTC medicines on NHS prescription runs to March 14

January 2 2018 Another consultation has commenced seeking views on restricting items which can be...

Dispensing error decriminalisation Bill discussed in Parliament

Dispensing error decriminalisation Bill discussed in Parliament

December 4 2017 The Bill which will give a statutory defence around dispensing errors is being...

  • Auditor flags up delays in roll out of electronic patient record in Wales

    Auditor flags up delays in roll out of electronic patient record in Wales

    Wednesday, 17 January 2018 10:07
  • RPS launches consultation on a proposed statement on the role of the pharmacist

    RPS launches consultation on a proposed statement on the role of the pharmacist

    Monday, 08 January 2018 14:08
  • CQC will get powers to extend coverage to include online medical services

    CQC will get powers to extend coverage to include online medical services

    Thursday, 04 January 2018 11:39
  • Second consultation on restricting OTC medicines on NHS prescription runs to March 14

    Second consultation on restricting OTC medicines on NHS prescription runs to March 14

    Tuesday, 02 January 2018 12:50
  • Dispensing error decriminalisation Bill discussed in Parliament

    Dispensing error decriminalisation Bill discussed in Parliament

    Monday, 04 December 2017 15:13

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a lady pharmacist talking to patient cbSeptember 20 2017

The NHS is set to encourage greater uptake of biosimilar medicines in an attempt to cut overall spending on medicines.

Simon Stevens, NHS England Chief Executive, has announced a number of measures to use new technologies and innovations to transform patient care. Among his proposals are to:

  • accelerate and widen the uptake of biosimilars with estimated savings of up to £300m a year by 2021;
  • take up new oral treatments for hepatitis C which could save NHS England more than £50m and save “thousands more lives”;
  • expand the “test-bed programme testing the treatments and care models of tomorrow”.

NHS England says that more biological medicines are due to lose patent exclusivity and more biosimilar medicines are expected to come into the marketplace. “Biosimilars that are already delivering safe, effective treatment for patients and cost savings for the NHS,” include:

  • biosimilar infliximab, used to treat rheumatology conditions and inflammatory bowel disease, which came on the market in March 2015, and is currently being used by 80% of patients;
  • biosimilar etanercept, used to treat rheumatology conditions, which became available in April 2016, and 58% of patients are using it.

“Switching to these two latest biosimilars has already saved the NHS approximately £160 million per annum.”

Earlier this year, biosimilar rituximab, used in cancer and rheumatoid arthritis, became available, and biosimilar adalimumab will become available in 2018, for use in rheumatology conditions and inflammatory bowel disease. “This will offer a biosimilar alternative to the current medicine which accounts for the highest spend in hospitals – more than £300 million in 2015-16,” said NHS England.

“The introduction of lower cost biosimilar medicines has the dual advantage of also driving down the cost of the original drug. For example, the cost per defined daily dose for infliximab has fallen by nearly two-thirds from £16.80 to £6.84.”

Link:
NHS England announcement        

Legal & Policy News

January 17 2018 Delays and issues with functionality in the electronic patient record are causing frustration, the Wales Audit Office has warned. It is also unclear whether intended benefits are...
January 16 2018 A range of information sheets relating to dental and oral health have been issued for use in pharmacies.